Appia Bio
Mitchell Kronenberg, PhD, is president and CSO of the La Jolla Institute for Immunology. He is an internationally recognized scientist and one of the most highly cited immunologists in the world, with notable deep expertise in NKT and other T cell subtypes. Over the years, Dr. Kronenberg has received many awards, including a prestigious Merit Award for scientific achievement from the National Institutes of Health and the Distinguished Service Award by the American Association of Immunologists. Dr. Kronenberg received his PhD from Caltech and completed his undergraduate studies at Columbia University.
This person is not in the org chart
This person is not in any offices
Appia Bio
Appia Bio is an early-stage biotechnology company based in Los Angeles, California. Founded in 2020, Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. With its ACUA (Appia Cells Utilized for Allogeneic) technology platform, Appia Bio leverages the biology of lymphocyte development with chimeric antigen receptor (CAR) and T-cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-iNKT) cell subtypes from hematopoietic stem cells (HSCs).